Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Hazard Ratio01:12

Hazard Ratio

103
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
103
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.

Journal for immunotherapy of cancer·2026
Same author

Case Report: durable response to pulsed electric field ablation in combination with immune checkpoint inhibitors in HER2-low breast cancer through activation of interferon signaling.

Frontiers in oncology·2026
Same author

Capturing the inflammatory landscape within kidney compartments of human diabetic kidney disease: a digital spatial profiling study.

Frontiers in endocrinology·2026
Same author

Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy.

Frontiers in immunology·2026
Same author

Spatial single-cell multiomics reveals peripheral immune dysfunction in Parkinson's and inflammatory bowel disease.

NPJ Parkinson's disease·2026
Same author

Postpartum breast cancer: evidence for a distinct phenotype.

Journal of the National Cancer Institute·2026

Related Experiment Video

Updated: Jun 15, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive

Saranya Chumsri1, Tanmayi Pai1, Yaohua Ma2

  • 1Mayo Clinic Florida, Jacksonville, FL.

Journal of the National Comprehensive Cancer Network : JNCCN
|August 27, 2024
PubMed
Summary

The Clinical Treatment Score post-5 years (CTS5) is not effective for predicting late recurrence in HER2-positive breast cancer treated with trastuzumab. New models are needed for this patient group.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

231

Related Experiment Videos

Last Updated: Jun 15, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

231

Area of Science:

  • Oncology
  • Clinical Trials
  • Breast Cancer Research

Background:

  • The Clinical Treatment Score post-5 years (CTS5) is a validated tool for risk stratification of late recurrence in hormone receptor-positive (HR+), HER2-negative breast cancer (BC).
  • Limited data exist regarding the efficacy of CTS5 in HR+, HER2-positive (HER2+) BC.

Purpose of the Study:

  • To evaluate the performance of the CTS5 score in predicting late recurrence in patients with HR+, HER2+ BC.
  • To assess the association of CTS5 with recurrence-free survival (RFS) in this specific patient population.

Main Methods:

  • Analysis of data from 1,862 patients with HR+, HER2+ BC from the NCCTG N9831 and NSABP B-31 clinical trials.
  • Evaluation of CTS5 score and its components against RFS in patients who received adjuvant trastuzumab.

Main Results:

  • The CTS5 score was significantly associated with RFS overall (HR, 1.35; P=.002) but not in patients receiving trastuzumab (HR, 1.29; P=.07).
  • CTS5 risk categories did not significantly correlate with RFS. Paradoxically, higher tumor grade was linked to better outcomes (HR, 0.71; P=.05).
  • Late recurrences (5-10 years) occurred in 10.6% of low-risk, 5.6% of intermediate-risk, and 9.8% of high-risk CTS5 categories.

Conclusions:

  • The CTS5 model is not a reliable predictor of late recurrence in HR+, HER2+ BC patients treated with adjuvant trastuzumab.
  • There is a critical need for developing novel prognostic models tailored for HR+, HER2+ BC patients receiving trastuzumab therapy to better predict late recurrence risk.